ACTRN12622000930785已完成4 期
Efficacy and safety of Artemether-Lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in different sentinel site in Sudan
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 212
研究概览
简要总结
Out of the 264 targeted sample, 212 (86, 83 and 43 at Blue Nile, Kassala and Sennar, respectively) patients of which 193 (72 at Blue Nile, 82 at Kassala and 39 at Sennar) reached the study endpoints during the 28-day follow-up. Per-protocol analysis showedPCR corrected artemether-lumefantrine cure rates of 95.8% in Blue Nile, 96.3% in Kassala and 89.7% in Sennar. No K13 mutations markers for K13 mutations, amplification of plaspepsin 2 and madr-1 genes were not observed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 6 Months 至 o limit（—）
- 性别
- All
入选标准
- •1.Age above six months excluding unmarried females of child bearing age (from 12 years).
- •2.mono-infection with P. falciparum confirmed by positive blood smear (i.e. no mixed infection);
- •3.parasitaemia of 1000–100000 asexual parasite per microliter forms;
- •4.presence of axillary temperature equal or greater than 37.5 degrees centigrade or history of fever during the past 24 h;
- •5.ability to swallow oral medication;
- •6.ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- •7.informed consent from the patient or from a parent or guardian in the case of children aged less than age of majority;
- •8.informed assent from any minor participant aged from 12 to 17 years; and
- •9.consent for pregnancy testing from married female of child-bearing age
排除标准
- •1. presence of general danger signs in children aged under 12 years or signs of severe falciparum malaria according to the definitions of WHO;
- •2. unmarried female in the child bearing age
- •3. weight under 5 kg;
- •4. mixed or mono-infection with another Plasmodium species detected by microscopy;
- •5. presence of severe malnutrition defined as a child aged between 6-60 months whose weight-for-high is below –3 z-score
- •6. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- •7. regular medication, which may interfere with antimalarial pharmacokinetics;
- •8. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
- •9. a positive pregnancy test.
- •10. Unable to or unwilling to take pregnancy test or to use contraception for women of child-bearing age (defined as age above 12 years and sexually active)
研究者
相似试验
已完成
4 期
Efficacy and safety of artemether-lumefantrine for the treatment ofuncomplicated Plasmodium falciparum malaria in Nangarhar andLaghman, AfghanistaMalariaACTRN12622000873729Ministry of Public Health Afghanistan123
已完成
4 期
Efficacy and safety of Artemether-Lumefantrine and dihydroartimisininne-pipraquine for the treatment of uncomplicated Plasmodium falciparum malaria in different sentinel site in SudaInfection - Studies of infection and infectious agentsMalariaACTRN12618001800213Ministry of Health362
尚未招募
不适用
Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in AngolaInfection - Studies of infection and infectious agentsMalariaACTRN12615000107527Ministry of Health600
已完成
4 期
Efficacy and safety of Artemether - Lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in in sentinel sites in Mozambique.Infection - Studies of infection and infectious agentsMalariaACTRN12616001680459Ministry of Health352
已完成
4 期
Efficacy and safety of artemether-lumefantrine (AL) combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in 4 Tribal dominating states in India: Madhya Pradesh, Maharashtra, Chhattisgarh and OdishaInfection - Studies of infection and infectious agentsMalariaACTRN12616001478404Indian Council of Medical Research, (ICMR) Ministry of Health & Family welfare.352